Oculis acquires Privosegtor rights in Accure deal
Oculis (NASDAQ:OCS) signed an agreement to acquire worldwide development and commercial rights to Privosegtor (ACT-01) from Accure Therapeutics, along with rights to an early-stage neurology candidate known as ACT-02.










